|
Match
|
Document |
Document Title |
|
|
US20110002989 |
METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD
The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment,... |
|
|
US20140308293 |
RECONSTITUTION METHOD FOR HIGH CONCENTRATION DRY PROTEIN FORMULATIONS
The present invention relates to the provision of a novel method for the reconstitution of dry formulations comprising biomolecules, and in particular, to dry protein formulations, and to... |
|
|
US20130172291 |
RETINAL CYCLODEXTRIN ACETALS AND HEMIACETALS FOR TREATING SKIN COMPLEXION DISORDER
The present invention discloses certain polyene cyclodextrin acetals and hemiacetals that are effective in providing skin clarification, which is useful for the treatment of acne, and skin... |
|
|
US20120289479 |
Materials and Methods Related to Sodium/Potassium Adenosine Triphosphate and Cholesterol
This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation... |
|
|
US20140228318 |
Curcumin formulations and methods for making such formulations
The present invention provides cyclodextrin-curcumin inclusion complexes, self-assemblies thereof; methods for making such inclusion complexes and self-assemblies, and methods for their use. |
|
|
US20130123214 |
USE OF DELTA TOCOPHEROL FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS
This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of delta tocopherol in the treatment of diseases and... |
|
|
US20140107067 |
COMPOSITIONS COMPRISING DIETARY FAT COMPLEXERS AND METHODS FOR THEIR USE
This invention relates to fat containing consumable food products comprising α-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat,... |
|
|
US20120309712 |
Compositions Comprising Dietary Fat Complexer and Methods for Their Use
This invention relates to fat containing consumable food products comprising α-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat,... |
|
|
US20110008325 |
Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid Prepared from a Unit Dose Suspension
An inhalable unit dose liquid formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The... |
|
|
US20110028431 |
ORAL MUCOADHESIVE DOSAGE FORM
A direct compression formulation suitable for preparing buccal and/or sublingual and dosage forms incorporates a combination of a non-ionic polymeric solubility enhancer, a mucoadhesive polymer, a... |
|
|
US20120035130 |
Chirally Correct Retinal Cyclodextrin Acetals for Clarifying Skin Complexion
The present invention discloses certain chirally correct polyene cyclodextrin acetals and hemiacetals (formula I) that are effective in providing skin clarification, which is useful for the... |
|
|
US20120017924 |
COATED NICOTINE-CONTAINING CHEWING GUM, MANUFACTURE AND USE THEREOF
A coated chewing gum product for the delivering of nicotine in any form to a subject by a rapid transmucosal uptake in the oral cavity comprising at least one gum core, nicotine in any form and/or... |
|
|
US20140378401 |
Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly... |
|
|
US20150065457 |
METHOD OF USING CYCLODEXTRIN
Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes. |
|
|
US20110305639 |
METHOD AND FORMULATION FOR REDUCING AGGREGATION OF A MACROMOLECULE UNDER PHYSIOLOGICAL CONDITIONS
The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of certain cyclodextrins... |
|
|
US20140038918 |
TREATMENTS FOR RETINAL DISORDERS
The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric,... |
|
|
US20150209337 |
NICOTINAMIDE DERIVATE IN THE TREATMENT OF ACUTE CORONARY SYNDROME
The present invention relates to the use of a nicotinamide derivative in the treatment acute coronary syndrome (ACS) and pharmaceutical compositions used in such treatment. |
|
|
US20080182821 |
Anti-Inflammatory and/or Analgesic Composition For the Intestine Comprising Branched Maltodextrins
The invention concerns a fiber-enriched anti-inflammatory and/or analgesic composition for the intestine, characterized in that it comprises branched maltodextrins having between 15 and 35% of... |
|
|
US20140206643 |
PRE-MIXED, READY-TO-USE IV BOLUS NICARDIPINE COMPOSITIONS AND METHODS OF USE
Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and... |
|
|
US20120214761 |
PRE-MIXED, READY-TO-USE IV BOLUS NICARDIPINE COMPOSITIONS AND METHODS OF USE
Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and... |
|
|
US20110028413 |
Methods of Reducing Methotrexate Nephrotoxicity
The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs such as methotrexate. The invention provides compositions comprising a substituted... |
|
|
US20140296180 |
CYCLIC OLIGOSACCHARIDES FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTION
Compounds which inhibit Wza-mcdiated polysaccharide transport are useful in the prevention or treatment of bacterial infection, in particular of E. coli infection. The compounds are typically... |
|
|
US20150202308 |
BUDESONIDE FORMULATION
The invention provides budesonide inhalation formulations containing cyclodextrins. |
|
|
US20120015039 |
SUSTAINED RELEASE OF NUTRIENTS IN VIVO
Nutritional compositions delivered in vivo in a time controlled manner sustainable over long periods of time, provide enhancing athletic performance, increased hand/eye coordination and... |
|
|
US20050171057 |
Pantoprazole cyclodextrin inclusion complexes
An inclusion complex formed from pantoprazole and cyclodextrin is described. |
|
|
US20150018307 |
DEODORANT COMPOSITIONS
A deodorant composition contains β-cyclodextrin, a fixative, a preservative, and a solvent. |
|
|
US20120083467 |
DEODORANT COMPOSITIONS
A deodorant composition contains β-cyclodextrin, a fixative, a preservative, and a solvent. |
|
|
US20110071110 |
Water Dispersible Policosanol Cyclodextrin Complex and Method of its Production
Disclosed is a formulation of policosanol with natural cyclodextrins resulting in a water dispersible form of policosanol. The disclosed process provides an economical commercial method for making... |
|
|
US20150024055 |
ENHANCED IMMEDIATE RELEASE FORMULATIONS OF TOPIRAMATE
The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These... |
|
|
US20120263667 |
COMPOSITION AND METHOD FOR MODULATING AND MAINTAINING VAGINAL BACTERIAL FLORA AND VAGINAL ACIDITY
The present invention relates to the use of benzoic acid and/or its sodium salt in combination with saccharide(s) as active components in the manufacture of a vaginal composition for modulating... |
|
|
US20110251157 |
Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid
An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can... |
|
|
US20150216895 |
CYCLODEXTRIN FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
The invention provides for methods of treating lysosomal storage disorders and/or reduction of non-cholesterol lipids, using cyclodextrin compounds, including in combination with other... |
|
|
US20130202601 |
ASSAYS, METHODS AND KITS FOR PREDICTING RENAL DISEASE AND PERSONALIZED TREATMENT STRATEGIES
Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular... |
|
|
US20150065458 |
Composition for Inactivating an Enveloped Virus
The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped... |
|
|
US20140235574 |
ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD
An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin... |
|
|
US20120053145 |
ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD
An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin... |
|
|
US20120171282 |
GINKGO BILOBA EXTRACT WITH A STANDARDISED GINKGO FLAVONE GLYCOSIDES CONTENT DEPRIVED OF THE PAF-ANTAGONIST TERPENIC FRACTION, AND COMPOSITIONS CONTAINING IT, FOR THE PREVENTION AND TREATMENT OF CIRCULATORY, COGNITIVE, GERIATRIC AND SENSORY DISORDERS
Disclosed is a Ginkgo biloba extract substantially devoid of PAF-antagonist activity. |
|
|
US20050142123 |
Water-dispersible coenzyme q10 dry powders
Novel powder compositions comprising droplets of Coenzyme Q-10 dispersed in a matrix of a modified polysaccharide or a gelatin are obtained by emulsifying Coenzyme Q-10 in a solution of the matrix... |
|
|
US20130039975 |
Liposomes Containing Prostaglandin E1 (PGE1), Formulations Containing Them and Their Use
Unilamellar liposomes comprising PGE1 and/or PGE1-α-cyclodextrin combined with carnitine, in which there are hydrophilic polymers on the external surface of the liposomes are described. |
|
|
US20130209444 |
NON-ANTICOAGULANT SULFATED OR SULFONATED POLYSACCHARIDES
The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations... |
|
|
US20120165292 |
METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass... |
|
|
US20070014833 |
Treatment of eye disorders with sirtuin modulators
Sirtuin modulators, particularly sirtuin activators, are useful in treating vision impairment. In general, the sirtuin modulators inhibit the progression of vision impairment resulting from... |
|
|
US20120077774 |
COMPOSITIONS AND THEIR USE FOR REMOVING CHOLESTEROL
The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached... |
|
|
US20120156296 |
ANTIOXIDANTS IN FISH OIL POWDER AND TABLETS
This invention relates to antioxidants and combinations of antioxidants used to prevent oxidation of pharmaceutical and nutraceutical products in the form of powders, granulates, tablets,... |
|
|
US20140274949 |
PERSONAL CARE COMPOSITIONS
A composition suitable for topical application, for example, is provided. In some examples, the composition can include particular cyclic oligosaccharides, a fragrance, and a volatile solvent. The... |
|
|
US20110152216 |
ANAESTHETIC COMPOSITION
A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of a... |
|
|
US20120316134 |
ANAESTHETIC COMPOSITION
A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of water... |
|
|
US20110009362 |
SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF
Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state... |
|
|
US20130090371 |
METHODS AND COMPOSITIONS FOR INHIBITION OF BETA2-ADRENERGIC RECEPTOR DEGRADATION
The present invention generally relates to compositions and kits comprising a β2-AR agonist and a modulator of a β2-AR regulator gene, where the modulator of the β2-AR regulator gene inhibits the... |
|
|
US20140171388 |
COMPOUND FOR TREATING CARTILAGE DISORDERS
The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be... |